SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer. - Phoenix JT; Budreika A; Schmeck DA; Kostlan RJ; Ferrari MG; Young KS; Rogers CS; Deegan CD; Bienko MW; Bergom HE; Boytim E; Brown RM; et al. (BioRxiv : the preprint server for biology, 2025)